ESR1 and breast carcinoma: According to the LNIC50 thresholds set in the current study, all nine bortezomib-sensitive breast cancer cell lines were estrogen receptor-negative (5/9 triple-negative), whereas all four bortezomib-insensitive cell lines were estrogen receptor-positive.